Abstract: The objective of this study is to evaluate the effectiveness of pamidronate for the treatment of chronic neuropathic pain refractory to previous management. Intravenous pamidronate (60 mg/day for 3 days) was administered to 2 adolescents with neuropathic pain refractory to previous multidisciplinary treatments. Pain intensity, functional improvement, and adverse effects were evaluated. There were no significant reductions in pain intensity or improvements in function initially or at follow-up at 1 week, 1 month and 4 months. Minor side effects included myalgia and skeletal pain that were relieved by acetaminophen. There was no long-term morbidity. In contrast to recent positive reports in adults, pamidronate was not effective in decreasing pain or improving function in 2 adolescents with chronic neuropathic pain. Pamidronate may be effective only when pain is accompanied by abnormal bone density. Future trials should include scans to document bone density pretherapy and posttherapy.
C omplex regional pain syndrome type I (CRPS I) is characterized by burning pain and variable autonomic symptoms (mottling, cyanosis, coldness, swelling) and trophic changes (altered hair and nail growth, muscle atrophy, osteoporosis). Pediatric patients often present with a history of minor trauma or repeated stress injury, although many are unable to recall a single precipitating event leading to the onset of their pain. CRPS I symptoms significantly interfere with quality of life and daily functioning; pain intensity and functional disability are often disproportionate to the initial trauma. 1, 2 As for other chronic pain disorders affecting children, several factors usually contribute to the persistence of this pain syndrome, necessitating a multidisciplinary multimodal approach of pharmacological, physical, and psychologic therapies to address each responsible factor. 3, 4 With the failure of this approach to alleviate pain in these 2 patients, alternative therapies were explored.
Positive results with the use of various bisphosphonates in adults with CRPS I refractory to multimodal therapy led us to consider their use in our 2 adolescent patients. Bisphosphonates alleviate bone pain in disorders such as malignant bone disease, with their specific action varying according to their active side chains. 5, 6 Pamidronate inhibits bone resorption through its potent osteoclastic affect on bone. CRPS I might exert a potential trophic effect on bone in the form of osteoporosis, as suggested by studies with adults.
Various bisphosphonates have been evaluated as treatments for CRPS I in adults. We proposed to evaluate the feasibility and effectiveness of pamidronate in a pilot trial for 2 adolescents with CRPS I.
PATIENTS AND METHODS
Two adolescents with CRPS I had persistent pain and disability despite receiving multiple pharmacologic, physical, and psychologic therapies throughout a 2.5-year follow-up, as shown in Table 1 .
Diagnosis of CRPS I was made in both adolescents based on history and physical examination. Diagnostic investigations were normal (ie, laboratory, radiologic exams). Bone density studies were not performed on either patient. In both patients, the neuropathic pain was associated with mechanical allodynia, primary and secondary hyperalgesia, diffuse tenderness to palpation, reduced range of motion, and symptoms aggravated by physical activity of the affected area. The affected extremities exhibited variable signs of autonomic dysfunction, edema (patient 1), and decreased temperature (patient 2), whereas neither had documented color or trophic hair or nail changes. Table 1 summarizes the past medical histories of the 2 adolescents prior to starting the treatment with pamidronate. Both patients had symptoms of depression including changes in mood, poor cognitive functioning (difficulty concentrating) leading to deterioration in school performance, social withdrawal, and sleep disturbances. Patient 1 also experienced lack of appetite. Both patients received psychiatric treatment including a combination of relaxation training, cognitive-behavioral therapy, self-hypnosis, and individual psychotherapy. Patient 2 attended 42 psychiatric sessions, and Patient 1 attended 33 psychiatric sessions prior to the commencement of pamidronate therapy. These 2 adolescents were resistant to an aggressive multidisciplinary treatment of both neuropathic pain and depression for a 2.5-year treatment period prior to starting the pamidronate.
Both adolescents were treated with pamidronate after obtaining patient and parent written consent. Upon arrival in our outpatient ambulatory care unit, basic vital signs were recorded along with height and weight. Intravenous cannulation was established, and blood work was monitored for calcium prior to pamidronate administration and daily at the end of infusion. The dose of pamidronate was 60 mg diluted in 600 mL of normal saline and administered at 180 mL/hour as per the hospital protocol. Vital signs were monitored hourly during the infusion. The infusion was repeated daily for 3 days for both patients. Both patients were given oral calcium supplements for the duration of therapy to minimize potential hypocalcemia. The patients were evaluated for side effects of the infusion while in the outpatient unit and were then evaluated at 1 week, 1 month, and at 4 months' follow-up. Outcome measures included a numeric rating scale for pain intensity (0 to 10). At follow-up, physical functioning was also assessed by looking at improvement in sleep and activities of daily living (ADL).
RESULTS
There were no significant reductions in pain intensity or improvements in function initially or at follow-up at 1 week, 1 month, and 4 months. Patient 1 experienced no change in pain intensity (8.5 pre-and postpamidronate) or improvement in physical functioning such as improvement in sleep or activities of daily living (ADL) during the follow-up assessments at 1 and 4 months (Tables 2 and 3) . Patient 2 had an increase in pain intensity from 8.5 pre-to 10 postpamidronate noted at 1 month. This had decreased to 8.5 by the 4-month follow-up. Patient 2 had no improvement in his physical functioning in follow-up. During the hospital stay, both patients experienced some side effects. Both patients had recorded small decreases in calcium levels, but no clinical evidence of hypocalcemia was present. In addition, both patients experienced myalgias, which resolved with acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs). These complaints were still present at 1-week follow-up.
DISCUSSION
Few studies have evaluated pharmacologic or multimodal therapies for CRPS I. Although tricyclic antidepressants and gabapentin are well-established analgesics for these conditions in adults, evidence for efficacy in children is confined to case reports or very small case series. 7, 8 Only 1 randomized controlled trial on 28 children has been conducted to evaluate multimodal approaches for CRPS I. Lee et al showed that a 6-week course of cognitive-behavioral therapy combined with either 3 times weekly or once-weekly physiotherapy sessions reduced pain and disability in children. 9 Moreover, no study has yet evaluated what treatments work for those children and adolescents who do not respond to a multimodal treatment approach.
Various bisphosphonates have been evaluated as treatments for CRPS I in adults. Alendronate, in a dosage of 7.5 mg/day intravenously for 3 days, was administered in a randomized and double-blinded placebo controlled trial of 20 adults with CRPS I. Patients had improved pain, tenderness, swelling, and improvement in motion within the first 2 weeks, but a high relapse rate of .40% in the 12 month follow-up makes its effectiveness doubtful. 10 Clodronate, in a dosage of 300 mg/day intravenously for 10 days, was administered in a randomized and double-blinded placebo controlled trial of 32 adults with CRPS I. 11 Patients had improved pain, swelling, and active range of motion at 40 days and at the 180-day follow-up, with 30 patients significantly improved or asymptomatic. No adverse events related to treatment occurred in this study; however, a 10-day course of the intravenous therapy was required. Interestingly, in their paper, Varenna et al 11 proposed that in addition to the effect of clodronate on osteoclastic activity, it may also have an effect on afferent pain nerve fibers, which may help explain its effect on pain modulation. More recently, pamidronate, in a dosage of 60 mg/day intravenously for 3 days, was administered in a nonrandomized clinical trial of 29 adults with CRPS I. 12 Patients had improved pain and functional improvement at 45 days. After reviewing the literature on the use of bisphosphonates in the pediatric population, the most experience in children is with pamidronate. It is currently the accepted therapy for osteogenesis imperfecta. 13 Pamidronate has been recommended for use more recently in cases of congenital and acquired forms of osteoporosis.
14 There is very little data in children with the use of alendronate and clodronate.
Our negative findings on the effectiveness of pamidronate for these adolescents contrast with the positive results in a recent trial with adults. Kubalek et al reported that pain resolved completely for 86.2% of the adult patients and function improved for 70% on day 45 of follow-up. 12 In their trial, all patients had a bone scintigraph suggestive of CRPS I prior to starting therapy revealing abnormal bone density. Of the 5 patients who had had their pain syndromes for greater than 1 year, 4 responded positively to the pamidronate therapy.
The discrepancy in effectiveness of pamidronate between our trial in 2 adolescents and Kubalek et al's trial in 29 adults may be attributed to differences in our sample pain conditions, either in bone density levels or individual patient characteristics. Documented abnormal bone density was present in all patients in the Kubalek et al 12 study but was not known in our trial. Although both adolescents had normal radiographs, we believed that pamidronate might be beneficial. Other reasons for lack of efficacy may be related to different growth and development issues in the pediatric patient and may also reflect the presence of clinical depression. The discrepancy could also be explained by questioning the benefits of pamidronate that Kubalek et al have concluded. Might the results of the Kubalek et al study have been different if a placebo-controlled trial had been used? Finally, with the failure of symptom-focused strategies as espoused by Sherry et al, 15 the previous failure of such therapies in our patients could also be secondary to central sensitization.
Moreover, the pediatric patients have unique factors and individual characteristics that may differentiate them from the adult population in mediating the treatment response. The adult population as presented in the Kubalek et al study had a variety of disorders associated with the etiology of their pain such as diabetes (34%), trauma (31%), drugs (10%) cancer (10%), and idiopathic (6.9%) as a primary etiology. The causative etiology in our patients was similar in that trauma was likely the cause in both. In contrast to both of our patients, though, there was no documentation or treatment of depression noted in the adult study patients. The adolescents in our trial showed evidence of clinical depression and social withdrawal in addition to unremitting pain. Although many children with chronic pain have behavioral limitations due to weakness or pain, for some children, excessive physical disability emerges as a significant separate problem. Recent attention is focusing on this subset of children. In their treatment program, McGrath and Hillier immediately identify the problem to families as 2-fold, a chronic pain problem and a disability problem, to emphasize that all the child's disability behaviors are not directly related to the pain level. 16 Bursch et al have coined the term Pain-Associated Disability Syndrome to describe these children. 17 This subset of patients with chronic pain has severe difficulties in functioning and does not respond to the typical multimodal program. Acute symptom-focused assessment and treatment strategies have not led to acceptable resolution of these problems.
In conclusion, although promising results have been shown with the use of intravenous pamidronate in adults with CRPS I, our 2 patients showed no benefit. Our case reports do not support the use of pamidronate for pediatric patients with CRPS I. Future studies should document bone density pre-and posttherapy and define the characteristics of the individual with CRPS I prior to commencing bisphosphonate therapy. 
